Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cangju Qinggan Jiangzhi decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine. It is primarily indicated for the treatment of non-alcoholic fatty liver disease (NAFLD), specifically targeting patients with the TCM syndrome of liver stagnation and spleen deficiency combined with dampness. The decoction is designed to clear liver heat, resolve dampness, and reduce lipid accumulation in the liver. As a multi-herb formulation, it likely exerts its therapeutic effects through pleiotropic pathways, including the regulation of lipid metabolism and the reduction of hepatic inflammation. It is currently being evaluated in clinical studies to assess its efficacy in improving liver function and metabolic parameters in NAFLD patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cangju qinggan jiangzhi decoction.